

52-4867



amrad corporation limited
abn 37 006 614 375
576 swan street richmond
victoria australia 3121
telephone (61 3) 9208 4000
facsimile (61 3) 9208 4356
<http://www.amrad.com.au>



02015209

To: The Securities and Exchange Commission
Company:
Fax: 0011 1 202 942 9624
From: Robyn Fry - Company Secretary
Fax: (+61 3) 9208 4356
Date: 18 February 2002
Pages: 18.
Including cover page

SUPPL

This document and any following pages are intended solely for the named addressee, are confidential and may contain legally privileged information. The copying or distribution of them or any information they contain, by anyone other than the addressee, is prohibited. If you have received this document in error, please let us know by telephone, and then return it by mail to the address above. We shall refund your costs of doing so.

FACSIMILE COVER SHEET

Amrad Corporation Limited

Please find attached information being furnished by Amrad Corporation Limited to the Securities and Exchange Commission.

A handwritten signature in dark ink, appearing to read "R. Fry".

Robyn Fry
General Counsel & Company Secretary

PROCESSED

FEB 25 2002

THOMSON
FINANCIAL

A handwritten signature in dark ink, followed by the date "2/19".



amrad corporation limited
abn 37 006 614 375
576 swan street richmond
victoria australia 3121

telephone (61 3) 9208 4000
facsimile (61 3) 9208 4352
<http://www.amrad.com.au>

FILE No.
82-4867

18 February 2002

Securities and Exchange Commission
Division of Corporate Finance
450 Fifth Street NW
WASHINGTON DC 20549
USA

Dear Sirs

AMRAD Corporation Limited
Rule 12g3-2(b) Exemption (File No. 82-4867)

The enclosed information is being furnished by AMRAD Corporation Limited ("AMRAD") under paragraph (b)(1)(i) of Rule 12g3-2 under the Securities Exchange Act of 1934 ("the Exchange Act"). AMRAD's file number is indicated in the upper right hand corner of each unbound page and the first page of each bound document furnished herewith.

In accordance with paragraphs (b)(4) and (b)(5) of the Rule, the documents furnished herewith are being furnished with the understanding that such documents will not be deemed "filed" with the Securities and Exchange Commission or otherwise subject to the liabilities of Section 18 of the Exchange Act, and that neither this letter nor the furnishings of such documents shall constitute an admission for any purpose that AMRAD is subject to the Exchange Act.

Yours sincerely

P.F. A handwritten signature in dark ink, appearing to read "Robyn Fry".

Robyn Fry
General Counsel & Company Secretary

FILE No.
82-4867Rule 12g3-2(b) Card Received from the SEC

ISSUER AMRAD Corporation Limited	FILE NO. 82- 4867
-------------------------------------	----------------------

9/4/98

This will advise that the issuer has been added to the list of those foreign private issuers that claim exemption pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Please be further advised that in order to continue to claim this exemption, the issuer must furnish to the Commission, on a timely basis, all information required by Rule 12g3-2(b). This includes all relevant documents since the date of your initial submission. The burden of furnishing such information rests with the issuer, even if it delegates that responsibility to another, and the staff will look to the issuer for compliance. If the issuer is a member of an affiliated or control group which normally prepares reports, press releases, etc., in a single document, a separate report must be submitted for each issuer that claims an exemption under the rule because separate files are maintained for each issuer.

ALL FUTURE SUBMISSIONS MUST PROMINENTLY INDICATE THE EXEMPTION NUMBER IN THE UPPER RIGHT HAND CORNER OF EACH UNBOUND PAGE AND THE FIRST PAGE OF EACH BOUND DOCUMENT PURSUANT TO THE IDENTIFICATION PROVISIONS OF THE RULE. FAILURE TO SO INDICATE WILL RESULT IN THE SUBMISSION BEING RETURNED TO THE SENDER AND THE SUBMISSION NOT BEING RECORDED, RESULTING IN POSSIBLE LOSS OF THE EXEMPTION.

**ASX**

AUSTRALIAN STOCK EXCHANGE

FILE No.
82-4867

Australian Stock Exchange Limited
ABN 98 008 824 691
Exchange Centre
Level 4, 20 Bridge Street
Sydney NSW 2000

PO Box H224
Australia Square
NSW 1215

Telephone 61 2 9227 0334
Facsimile 61 2 9227 0339
Internet <http://www.asx.com.au>
DX 10427 Stock Exchange Sydney

FACSIMILE**Department: COMPANY ANNOUNCEMENTS OFFICE****DATE: 18/02/2002****TIME: 10:33:41****TO: AMRAD CORPORATION LIMITED****FAX NO: 03-9208-4356****FROM: AUSTRALIAN STOCK EXCHANGE LIMITED
COMPANY ANNOUNCEMENTS OFFICE****PAGES: 1****SUBJECT: CONFIRMATION OF RECEIPT AND RELEASE OF ANNOUNCEMENT****MESSAGE:**

We confirm the receipt and release to the market of an announcement regarding:

Half Year Results Presentation Slides




AMRAD CORPORATION LIMITED

Clinical Development of Compounds for

Serious Chronic Human Diseases

Focused on Early Commercial Returns

Driving Assets Harder




Recent Management Changes



- Professor John Mills: Chairman
- Mr Henry Nordhoff : Non-executive Director
- Dr Sandra Webb: Managing Director
- Dr Jonathan Coates: Chief Scientific Officer


Clear Focus



FILE NO. 82-4867

3 Core Competencies

FILE No.
82-4867




Clinical Development Strategy




- AML clinical development utilising core competencies
 - Infectious Diseases
 - Allergy / Inflammation
 - Neurology
- Co – Development utilising skill of others
 - Targets where AML wishes to retain interest
- Partnered Development
 - With major Bio / Pharma groups world wide
 - Early financial benefits


AML Clinical Development




FILE NO.
82-4867

AML Clinical Development





Co - Development



FILE No. 82-4867


18-FEB-2002 11:19 FROM AMRAD CORPORATION TO 1001112029429624 P.14/16

Partnered Development



FILE No.
82-4867

18-FEB-2002 11:19 FROM AMRAD CORPORATION TO 1001112029429624 P.15/16




Forecast Milestones



amrad.

AML



Chronic Pain

AM336



Nerve Protection

Emfilermin



Hepatitis B

AM365



Forecast ASX Announcements



2002 2003

Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
↑	↑	↑	↑	↑	↑	↑	↑

Nerve Protection ★

Chronic Pain ★

Hepatitis B ★

Reproductive Health ★

Stroke ★




Forecast Milestones



amrad.

Co- Development
& Partnered




Reproductive
Health



AM424 Serono

Cardiovascular



AM133 Edwards


AM132 Aventis

Stroke



AM36 DevCo

Rheumatoid
Arthritis



CAT